Haematology clinical trials
Our haematology clinical trials deliver internationally recognised clinical research across blood cancers, benign haematology and advanced cellular therapies.
We provide patients with access to innovative treatments while partnering with industry, academia and healthcare organisations to shape the future of blood disorder care. The Clinical Trials Unit is a partnership between Monash Health, Monash University and the Hudson Institute of Medical Research. Our clinical trials portfolio includes studies evaluating:
- Chimeric Antigen Receptor (CAR) T-cell therapies (both autologous and allogeneic)
- Bispecific antibodies
- Antibody–drug conjugates
- Immune checkpoint inhibitors
- Other emerging cellular and immune-based therapies
The Haematology Clinical Trials Unit also provides expertise and operational support for CAR T-cell therapy studies undertaken across Monash Health in partnership with Monash University, collaborating with other specialties to facilitate the delivery of innovative cellular therapy trials beyond haematological malignancies.
Our Principal Investigators
Our multidisciplinary team of clinicians, researchers and clinical trial professionals is united by a shared commitment to advancing innovative therapies and improving the lives of people living with blood disorders.
Information for patients
Clinical trials provide eligible patients with access to new treatments while contributing to future advances in healthcare.
Current trials
Find out about the currently recruiting Haematology Clinical trials in the Monash Health Translational Precinct.
Why Partner with Us?
We are one of Australia's largest haematology clinical trial programs.
CAR-T Centre
Established infrastructure supporting advanced cellular therapies and immunotherapy studies utilising cutting edge infrastructure of the Hudson Cell Therapies platform.
Find out more from the Hudson Cell Therapies website.